MCID: ANL011
MIFTS: 41

Anal Canal Carcinoma malady

Cancer diseases, Endocrine diseases categories

Aliases & Classifications for Anal Canal Carcinoma

About this section

Aliases & Descriptions for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 8 9
Carcinoma of Anal Canal 8 61
 
Anal Canal and Perianal Gland Carcinoma 8
Anal Canal Cancer 8


Classifications:



External Ids:

Disease Ontology8 DOID:6126, DOID:0050688
NCIt39 C7489
SNOMED-CT56 285310000
ICD1025 C21.1

Summaries for Anal Canal Carcinoma

About this section
Disease Ontology:8 An anal canal cancer that derives from epithelial cells.

MalaCards based summary: Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to leukemia and adenocarcinoma. An important gene associated with Anal Canal Carcinoma is GLI1 (GLI family zinc finger 1), and among its related pathways are Validated targets of C-MYC transcriptional activation and Doxorubicin Pathway, Pharmacokinetics. The compounds slex and 5 aminosalicylic acid have been mentioned in the context of this disorder. Affiliated tissues include skin and prostate, and related mouse phenotypes are respiratory system and digestive/alimentary.

Related Diseases for Anal Canal Carcinoma

About this section

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 61)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia29.4TP53, PECAM1, NQO1, CDKN2A, NME1
2adenocarcinoma29.1CDKN2A, GLI1, NME1, TP53, NQO1, PECAM1
3actinic keratosis10.4TP53
4neuroblastoma10.2NME1, TP53
5breast cancer10.2TP53, NME1
6burns10.2
7anal carcinoma in situ10.2
8prostate adenocarcinoma10.2
9prostatitis10.2
10breast ductal carcinoma10.2TP53, NME1
11anal canal squamous cell carcinoma10.2
12anal canal adenocarcinoma10.2
13laryngeal carcinoma10.2NME1, TP53
14basal cell carcinoma10.2GLI1, TP53
15pancreatic cancer10.1GLI1, NQO1
16carcinoid syndrome10.1GLI1, NQO1
17xeroderma pigmentosum, variant type10.1TP53, NQO1
18gastric adenocarcinoma10.1NME1, GLI1
19lung cancer10.1TP53, CDKN2A
20cervical adenocarcinoma10.1NME1, CDKN2A
21oropharynx cancer10.1CDKN2A, TP53
22transitional cell carcinoma10.1NME1, TP53
23cervical intraepithelial neoplasia10.1NME1, CDKN2A
24li-fraumeni syndrome10.1TP53, CDKN2A
25nasopharynx carcinoma10.1CDKN2A, TP53
26uveal melanoma10.0NME1, CDKN2A
27barrett esophagus/esophageal adenocarcinoma10.0CDKN2A, TP53
28grade iii astrocytoma10.0TP53, CDKN2A
29esophageal cancer10.0TP53, CDKN2A
30brain cancer10.0PECAM1, TP53, GLI1
31oligodendroglioma10.0TP53, CDKN2A
32mesothelioma10.0PECAM1, CDKN2A
33sarcoma10.0GLI1, PECAM1, TP53
34papilloma10.0CDKN2A, TP53
35oral cancer10.0CDKN2A, TP53
36acute lymphoblastic leukemia, childhood10.0CDKN2A, NQO1
37squamous cell carcinoma, head and neck9.9TP53, CDKN2A
38multiple myeloma9.9TP53, CDKN2A
39laryngeal squamous cell carcinoma9.9CDKN2A, TP53, NME1
40malignant glioma9.9CDKN2A, TP53, GLI1
41chronic lymphocytic leukemia9.9PECAM1, TP53
42nasopharyngeal carcinoma9.9NME1, TP53, CDKN2A
43endometrial cancer9.9NME1, CDKN2A, TP53
44cervical cancer, somatic9.8CDKN2A, NME1, TP53
45colorectal cancer9.8CDKN2A, NME1, TP53
46bladder cancer, somatic9.8TP53, CDKN2A
47retinoblastoma9.8NME1, CDKN2A, TP53
48small cell cancer of the lung, somatic9.8TP53, CDKN2A, NQO1
49prostate cancer9.7PECAM1, TP53, GLI1, NQO1
50osteosarcoma, somatic9.7CDKN2A, NME1, GLI1, TP53

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to anal canal carcinoma

Symptoms for Anal Canal Carcinoma

About this section

Drugs & Therapeutics for Anal Canal Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Anal Canal Carcinoma

Search NIH Clinical Center for Anal Canal Carcinoma

Genetic Tests for Anal Canal Carcinoma

About this section

Anatomical Context for Anal Canal Carcinoma

About this section

MalaCards organs/tissues related to Anal Canal Carcinoma:

31
Skin, Prostate

Animal Models for Anal Canal Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Anal Canal Carcinoma:

35 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.4CDKN2A, GLI1, TP53, PECAM1
2MP:00053818.4PECAM1, TP53, GLI1, CDKN2A
3MP:00053798.2CDKN2A, GLI1, NME1, TP53
4MP:00107718.0NQO1, TP53, NME1, CDKN2A
5MP:00020068.0CDKN2A, GLI1, NME1, TP53, NQO1
6MP:00053807.9TP53, NME1, GLI1, CDKN2A
7MP:00053707.9PECAM1, NQO1, TP53, NME1, CDKN2A
8MP:00053977.8PECAM1, NQO1, TP53, NME1, CDKN2A
9MP:00053847.8PECAM1, NQO1, TP53, GLI1, CDKN2A
10MP:00053787.8NQO1, TP53, NME1, GLI1, CDKN2A
11MP:00053767.6CDKN2A, NME1, TP53, NQO1, PECAM1

Publications for Anal Canal Carcinoma

About this section

Articles related to Anal Canal Carcinoma:

(show top 50)    (show all 62)
idTitleAuthorsYear
1
Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities. (25903798)
2015
2
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. (24243447)
2014
3
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. (24472223)
2014
4
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. (24674573)
2013
5
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. (23674135)
2013
6
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. (21395883)
2012
7
Chemotherapy in the treatment of anal canal carcinoma. (22658644)
2012
8
Endobronchial metastases of anal canal carcinoma. (22055765)
2012
9
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. (21775274)
2011
10
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. (22331724)
2011
11
Anal canal carcinoma treatment results: the experience of a single institution. (21403412)
2011
12
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. (20472349)
2011
13
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. (20492729)
2010
14
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. (19399614)
2010
15
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. (19695047)
2009
16
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). (18490648)
2008
17
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). (18191265)
2008
18
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. (18505075)
2008
19
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. (18005443)
2007
20
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. (18060184)
2007
21
Anal canal carcinoma with Pagetoid spread: report of a case. (16794808)
2006
22
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. (16631268)
2006
23
Epidermal growth factor receptor expression in anal canal carcinoma. (15923158)
2005
24
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. (15890590)
2005
25
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. (15752894)
2005
26
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. (12788191)
2003
27
Analysis of a follow-up program for anal canal carcinoma. (11484975)
2001
28
Prognostic impact of CD31 antigen expression in anal canal carcinoma. (11677963)
2001
29
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. (11398611)
2001
30
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. (11395235)
2001
31
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? (10914829)
2000
32
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. (10914830)
2000
33
Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. (11277325)
2000
34
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. (10435803)
1999
35
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. (10523705)
1999
36
Human papillomavirus infection and p53 nuclear overexpression in anal canal carcinoma. (10374676)
1999
37
Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C. (9788412)
1998
38
Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases. (9778618)
1998
39
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? (9559628)
1998
40
Epidermoid anal canal carcinoma metastatic to the skin. A clinical mimic of prostate adenocarcinoma metastases. (7962940)
1994
41
Late recurrence following treatment of anal canal carcinoma. (1712526)
1991
42
Feasibility of non-surgical definitive management of anal canal carcinoma. (3384732)
1988
43
Our experience of conservative treatment of anal canal carcinoma combining external irradiation and interstitial implant: 32 cases treated between 1973 and 1982. (3338946)
1988
44
Feasibility of non-surgical definitive management of anal canal carcinoma. (3104242)
1987
45
Recurrent deletions of chromosomes 11q and 3p in anal canal carcinoma. (3570551)
1987
46
Treatment of anal canal carcinoma. (3919927)
1985
47
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. (6435851)
1984
48
Radiation therapy and chemotherapy in the treatment of primary anal canal carcinoma. (6831854)
1983
49
Definitive treatment of anal-canal carcinoma by means of radiation therapy and chemotherapy. (6813084)
1982
50
Primary radiation therapy in the treatment of anal canal carcinoma. (7172946)
1982

Variations for Anal Canal Carcinoma

About this section

Expression for genes affiliated with Anal Canal Carcinoma

About this section
Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for genes affiliated with Anal Canal Carcinoma

About this section

Compounds for genes affiliated with Anal Canal Carcinoma

About this section

Compounds related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 59)
idCompoundScoreTop Affiliating Genes
1slex449.9PECAM1, NME1
25 aminosalicylic acid449.9NQO1, PECAM1
317-(allylamino)-17-demethoxygeldanamycin449.8NQO1, NME1
43,3-diindolylmethane449.5NQO1, TP53
5aristolochic acid44 110.5TP53, NQO1
6dicoumarol449.5NQO1, TP53
7acnu449.5CDKN2A, TP53
8fluorouracil50 1110.5TP53, NQO1
9hpvs449.4TP53, CDKN2A
10olomoucine44 1110.4TP53, CDKN2A
115-methylcytosine44 2410.4CDKN2A, TP53
12indole-3-carbinol449.4TP53, NQO1
13hematoxylin449.4PECAM1, CDKN2A
14temozolomide44 1110.4TP53, CDKN2A
15hmba449.4TP53, CDKN2A
16aflatoxin b144 2410.4TP53, CDKN2A
17benzo(a)pyrene449.4TP53, NQO1
18o6-methylguanine449.4TP53, CDKN2A
19oxaliplatin44 50 1111.3TP53, NQO1
20depsipeptide449.3CDKN2A, TP53
21roscovitine449.3TP53, CDKN2A
22daunorubicin44 50 1111.2CDKN2A, NQO1
23melphalan44 50 1111.2TP53, NQO1
24flavopiridol44 1110.1TP53, CDKN2A
25bleomycin44 1110.1NQO1, TP53
26creatinine449.1NQO1, NME1, CDKN2A
27aspartate449.1NME1, CDKN2A, NQO1
28crcs449.1TP53, NME1, CDKN2A
29thymidine44 2410.0PECAM1, TP53, NME1
30bcnu449.0CDKN2A, TP53, NQO1
31thymidylate448.9TP53, NQO1, CDKN2A
32cytarabine44 50 1110.9CDKN2A, TP53, NQO1
33adriamycin448.9CDKN2A, TP53, NQO1
34camptothecin44 60 1110.9CDKN2A, NQO1, TP53
35arsenite44 249.9CDKN2A, TP53, NQO1
36agar448.9NQO1, NME1, CDKN2A, PECAM1
37n acetylcysteine448.9TP53, CDKN2A, NQO1
38actinomycin d448.9PECAM1, CDKN2A, TP53
39doxorubicin44 50 1110.8TP53, CDKN2A, NQO1
40cysteine448.8CDKN2A, NQO1, PECAM1, NME1
41paraffin448.6NME1, CDKN2A, PECAM1, TP53
42vegf448.6CDKN2A, NME1, TP53, PECAM1
435fluorouracil448.6CDKN2A, NQO1, TP53, NME1
44cisplatin44 50 60 1111.5NQO1, NME1, TP53, CDKN2A
45retinoic acid44 249.5PECAM1, TP53, NME1, CDKN2A
46cycloheximide448.5TP53, NQO1, PECAM1, CDKN2A
47h2o2448.5CDKN2A, NQO1, TP53, PECAM1
48progesterone44 28 60 24 1112.3NME1, CDKN2A, TP53
49estrogen448.1PECAM1, NQO1, TP53, NME1, CDKN2A
50serine448.1NME1, NQO1, CDKN2A, PECAM1, TP53

GO Terms for genes affiliated with Anal Canal Carcinoma

About this section

Cellular components related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nuclear bodyGO:00166048.7CDKN2A, TP53
2cytosolGO:00058297.7CDKN2A, GLI1, NME1, TP53, NQO1

Biological processes related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of neuron apoptotic processGO:00435259.2TP53, NQO1
2replicative senescenceGO:00903999.2CDKN2A, TP53
3positive regulation of cell cycle arrestGO:00711589.1CDKN2A, TP53
4cellular response to drugGO:00356909.1NME1, TP53
5Ras protein signal transductionGO:00072659.0CDKN2A, TP53
6negative regulation of cell proliferationGO:00082858.6TP53, NME1, CDKN2A
7positive regulation of transcription, DNA-templatedGO:00458938.4CDKN2A, GLI1, TP53

Molecular functions related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MDM2/MDM4 family protein bindingGO:00973719.0CDKN2A, TP53
2p53 bindingGO:00020398.7TP53, CDKN2A
3protein kinase bindingGO:00199018.5CDKN2A, NME1, TP53
4protein bindingGO:00055157.3CDKN2A, GLI1, NME1, TP53, NQO1, PECAM1

Sources for Anal Canal Carcinoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet